Conclusions: This investigation shows high accuracy for using tumor enhancement features on 1-month posttherapy MR imaging to predict residual disease after chemoembolization of HCC. (Source: Journal of Vascular and Interventional Radiology : JVIR)
View full post on MedWorm: HIPAA